INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 35 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $981,000 | – | 736,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $34,742,000 | 1.33% |
| PenderFund Capital Management Ltd. | 5,000,000 | $3,839,000 | 0.98% |
| Context Capital Management, LLC | 7,485,000 | $4,494,000 | 0.62% |
| Opti Capital Management, LP | 7,000,000 | $4,250,000 | 0.47% |
| Soros Fund Management | 32,298,000 | $19,611,000 | 0.37% |
| Shaolin Capital Management LLC | 7,000,000 | $4,175,000 | 0.29% |
| Weiss Asset Management LP | 3,500,000 | $2,084,000 | 0.09% |
| CSS LLC/IL | 2,825,000 | $1,681,000 | 0.06% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $137,000 | 0.02% |
| LAZARD ASSET MANAGEMENT LLC | 25,000,000 | $15,009,000 | 0.02% |